Literature DB >> 32793704

Tumor mutation burden in Chinese cancer patients and the underlying driving pathways of high tumor mutation burden across different cancer types.

Xiao-Dong Jiao1, Xiao-Chun Zhang2, Bao-Dong Qin1, Dong Liu2, Liang Liu3, Jian-Jiao Ni3, Zhou-Yu Ning4, Ling-Xiang Chen5, Liang-Jun Zhu5, Song-Bing Qin6, Shen-Peng Ying7, Xue-Qin Chen8, Ai-Jun Li9, Ting Hou10, Han Han-Zhang10, Junyi Ye10, Jingjing Zheng10, Shannon Chuai10, Yuan-Sheng Zang1.   

Abstract

BACKGROUND: Tumor mutation burden (TMB) has an important association with immunotherapy responses. TMB in the Chinese population has not been well established. Finding differences between the Chinese and Caucasian populations and elucidating the underlying biological mechanisms of high TMB might help develop more precise and effective means for TMB and immunotherapy response prediction.
METHODS: Chinese cancer patients fresh tissue (n=2,177), formalin-fixed, paraffin-embed (FFPE) specimens (n=3,294), and pleural fluid (n=189) were profiled using a 295- or 520-gene next-generation sequencing (NGS) panel. The association of the TMB status with a series of molecular features and biological pathways was determined using bootstrapping.
RESULTS: TMB, measured by 295- or 520-cancer-related gene panels, was correlated with whole-exome sequencing (WES) TMB based on the in silico simulation in The Cancer Genome Atlas cohort. The median TMB of our data was slightly higher than that from the Foundation Medicine Inc. (FMI) dataset. TMB was also slightly different within the same cancer type between the Chinese and Caucasian population. We discovered that the underlying pathways of TMB status varied greatly and sometimes had an opposite association with TMB across different cancer types. Moreover, we developed a 23-gene and a 16-gene signature to predict TMB prediction for lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), respectively, indicating a histology-specific mechanism for driving high-TMB in lung cancer.
CONCLUSIONS: TMB varies among different ethnic populations. Our findings extend the knowledge of the underlying biological mechanisms for high TMB and might be helpful for developing more precise and accessible TMB assessment panels and algorithms in more cancer types. 2020 Annals of Translational Medicine. All rights reserved.

Entities:  

Keywords:  Chinese; Tumor mutation burden (TMB); cancer-related gene panel; gene signature

Year:  2020        PMID: 32793704      PMCID: PMC7396744          DOI: 10.21037/atm-20-3807

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  29 in total

Review 1.  Where next for gefitinib in patients with lung cancer?

Authors:  Fiona Blackhall; Malcolm Ranson; Nick Thatcher
Journal:  Lancet Oncol       Date:  2006-06       Impact factor: 41.316

2.  Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.

Authors:  Matthew D Hellmann; Tudor-Eliade Ciuleanu; Adam Pluzanski; Jong Seok Lee; Gregory A Otterson; Clarisse Audigier-Valette; Elisa Minenza; Helena Linardou; Sjaak Burgers; Pamela Salman; Hossein Borghaei; Suresh S Ramalingam; Julie Brahmer; Martin Reck; Kenneth J O'Byrne; William J Geese; George Green; Han Chang; Joseph Szustakowski; Prabhu Bhagavatheeswaran; Diane Healey; Yali Fu; Faith Nathan; Luis Paz-Ares
Journal:  N Engl J Med       Date:  2018-04-16       Impact factor: 91.245

Review 3.  Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

Authors:  Emiliano Calvo; José Baselga
Journal:  J Clin Oncol       Date:  2006-05-10       Impact factor: 44.544

4.  A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing.

Authors:  Lizhen Zhu; Yanqin Huang; Xuefeng Fang; Chenglin Liu; Wanglong Deng; Chenhan Zhong; Jinghong Xu; Dong Xu; Ying Yuan
Journal:  J Mol Diagn       Date:  2017-12-19       Impact factor: 5.568

5.  Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.

Authors:  Emma Nolan; Peter Savas; Antonia N Policheni; Phillip K Darcy; François Vaillant; Christopher P Mintoff; Sathana Dushyanthen; Mariam Mansour; Jia-Min B Pang; Stephen B Fox; Charles M Perou; Jane E Visvader; Daniel H D Gray; Sherene Loi; Geoffrey J Lindeman
Journal:  Sci Transl Med       Date:  2017-06-07       Impact factor: 17.956

6.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

Authors:  Yihua Sun; Yan Ren; Zhaoyuan Fang; Chenguang Li; Rong Fang; Bin Gao; Xiangkun Han; Weidong Tian; William Pao; Haiquan Chen; Hongbin Ji
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

Review 7.  Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different.

Authors:  Chung-Han Lee; Roman Yelensky; Karin Jooss; Timothy A Chan
Journal:  Trends Immunol       Date:  2018-05-08       Impact factor: 16.687

8.  Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.

Authors:  Zachary R Chalmers; Caitlin F Connelly; David Fabrizio; Laurie Gay; Siraj M Ali; Riley Ennis; Alexa Schrock; Brittany Campbell; Adam Shlien; Juliann Chmielecki; Franklin Huang; Yuting He; James Sun; Uri Tabori; Mark Kennedy; Daniel S Lieber; Steven Roels; Jared White; Geoffrey A Otto; Jeffrey S Ross; Levi Garraway; Vincent A Miller; Phillip J Stephens; Garrett M Frampton
Journal:  Genome Med       Date:  2017-04-19       Impact factor: 11.117

9.  Signatures of mutational processes in human cancer.

Authors:  Ludmil B Alexandrov; Serena Nik-Zainal; David C Wedge; Samuel A J R Aparicio; Sam Behjati; Andrew V Biankin; Graham R Bignell; Niccolò Bolli; Ake Borg; Anne-Lise Børresen-Dale; Sandrine Boyault; Birgit Burkhardt; Adam P Butler; Carlos Caldas; Helen R Davies; Christine Desmedt; Roland Eils; Jórunn Erla Eyfjörd; John A Foekens; Mel Greaves; Fumie Hosoda; Barbara Hutter; Tomislav Ilicic; Sandrine Imbeaud; Marcin Imielinski; Marcin Imielinsk; Natalie Jäger; David T W Jones; David Jones; Stian Knappskog; Marcel Kool; Sunil R Lakhani; Carlos López-Otín; Sancha Martin; Nikhil C Munshi; Hiromi Nakamura; Paul A Northcott; Marina Pajic; Elli Papaemmanuil; Angelo Paradiso; John V Pearson; Xose S Puente; Keiran Raine; Manasa Ramakrishna; Andrea L Richardson; Julia Richter; Philip Rosenstiel; Matthias Schlesner; Ton N Schumacher; Paul N Span; Jon W Teague; Yasushi Totoki; Andrew N J Tutt; Rafael Valdés-Mas; Marit M van Buuren; Laura van 't Veer; Anne Vincent-Salomon; Nicola Waddell; Lucy R Yates; Jessica Zucman-Rossi; P Andrew Futreal; Ultan McDermott; Peter Lichter; Matthew Meyerson; Sean M Grimmond; Reiner Siebert; Elías Campo; Tatsuhiro Shibata; Stefan M Pfister; Peter J Campbell; Michael R Stratton
Journal:  Nature       Date:  2013-08-14       Impact factor: 49.962

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  3 in total

1.  Smoking status combined with tumor mutational burden as a prognosis predictor for combination immune checkpoint inhibitor therapy in non-small cell lung cancer.

Authors:  Li-Yue Sun; Wen-Jian Cen; Wen-Ting Tang; Ya-Kang Long; Xin-Hua Yang; Xiao-Meng Ji; Jiao-Jiao Yang; Ren-Jing Zhang; Fang Wang; Jian-Yong Shao; Zi-Ming Du
Journal:  Cancer Med       Date:  2021-09-01       Impact factor: 4.452

2.  [Expert Consensus on Tumor Mutational Burden for Immunotherapy in Lung Cancer].

Authors: 
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2021-11-20

3.  Influence of Different Age Cutoff Points on the Prediction of Prognosis of Cancer Patients Receiving ICIs and Potential Mechanistic Exploration.

Authors:  Rui Guan; Qiong Lyu; Anqi Lin; Junyi Liang; Weimin Ding; Manming Cao; Peng Luo; Jian Zhang
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.